New hemophilia shot shows early promise in small safety trial
NCT ID NCT05493631
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called MG1113, given as a shot under the skin, in 15 adults with severe hemophilia A or B. The main goal was to check safety and how the drug moves through the body. Participants received multiple doses to see if the drug is well-tolerated. Since this is a Phase 1 trial, it is too early to know if MG1113 will effectively control bleeding.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MG1113 (a biologic drug given as a shot under the skin)
What this could lead to
If successful, this could lead to a new treatment option for severe hemophilia that is easier to take than current therapies.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Much more research is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GC Biopharma Corp.
Yongin-si, Gyeonggi-do, 16924, South Korea